drug · small molecule
levacetylleucine
Marketedupdated 6mo agoby IntraBio Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for niemann-pick disease type c and 3 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying levacetylleucine
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 24, 2029
~2.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Apr 19, 2037method-of-use (U-4170)US 11400067
- Apr 19, 2037method-of-use (U-4284)US 12433862
- Apr 19, 2037method-of-use (U-4285)US 12433863
FDA exclusivities (2)
- Sep 24, 2031ODE-498Orphan Drug (7y)4.9y
- Sep 24, 2029NCENew Chemical Entity (5y)2.9y
News(5)
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…biospace · 1mo ago
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…biospace · 1mo ago
- Shionogi pays $2B to acquire a rare disease startupThe acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.biopharma_dive · 1mo ago
- Shionogi to pay $2B for IntraBio, a commercial rare disease biotechShionogi is buying an Austin, TX-based commercial biotech for $2 billion upfront, adding another medicine to the Japanese pharma's rare disease portfolio. The drugmaker is scooping up IntraBio and…endpoints · 1mo ago
- FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD dataPlus news about Biokin, Bristol Myers Squibb, Grünenthal and Johnson & Johnson. FDA approves ataxia-telangiectasia treatment: The agency approved the rare genetic disease treatment Aqneursa from th…endpoints · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that